-48%

est. 2Y upside i

Series D+

Empowering women. Period.

Rank

#2828

Sector

FemTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Qvin presents a moderate upside opportunity driven by its innovative, FDA-cleared Q-Pad™ technology for menstrual blood health testing and its first-mover advantage in a growing FemTech market.

Last updated: March 10, 2026

Bull (35%)+100%

Qvin successfully expands its Q-Pad™ platform beyond A1c testing to include a suite of critical women's health biomarkers (e.g., anemia, fertility, HPV), achieving rapid market adoption due to its non-invasive convenience and FDA clearance. Strategic partnerships with major healthcare providers accelerate growth, pushing revenue significantly higher and justifying a $200M+ valuation at exit, representing a 2x return from the current estimated valuation.

Base (30%)+30%

Qvin maintains its first-mover advantage in menstrual blood health testing, primarily growing its A1c testing market share. While expanding to a few additional biomarkers, growth is steady but faces competition from traditional diagnostic methods and slower-than-anticipated adoption. The company achieves a modest exit valuation of approximately $130M, providing a 30% upside from the current estimated valuation.

Bear (35%)-40%

Dominant incumbents like Labcorp OnDemand enter the non-invasive women's health diagnostic space with competing or superior technologies, or significantly expand their existing offerings, eroding Qvin's market share and pricing power. Regulatory hurdles for new biomarker tests prove more challenging, slowing product expansion. This leads to a down round or an acquisition at a significantly reduced valuation of $60M, resulting in a 40% loss for common stock holders after accounting for liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Based on an estimated $100M valuation and $24M in total funding, investors hold approximately $24M in liquidation preferences ahead of common stock.

Dilution Risk

moderate

With 24% of the estimated valuation already raised, further funding rounds are likely before an exit, which could lead to additional dilution for common stock holders.

Secondary Liquidity

none

As a private, venture-backed company at this stage, there is typically no active secondary market or tender offers for employee equity.

Questions to Ask at the Interview

Strategic questions based on Qvin's data — designed to show you've done your homework.

  • 1

    “How is Qvin planning to expand beyond A1c testing to other biomarkers, and what are the biggest regulatory and market adoption challenges for these new tests, especially given the high regulatory barrier for medical diagnostic devices?”

  • 2

    “Given the significant market presence of traditional diagnostic companies like Labcorp OnDemand, what is Qvin's strategy to capture and retain market share, particularly if incumbents develop similar non-invasive technologies or expand their offerings to directly compete?”

  • 3

    “With the 'Later Stage VC' funding and total capital raised of $24M, what is the anticipated timeline and preferred path to a liquidity event (e.g., IPO or acquisition) for employees holding equity, and how does the company plan to manage potential future dilution?”

Community

Valuation Sentiment

Our model estimates -48% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.